4 completed, 1 terminated. 3 Phase 1, 2 Phase 2, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Completed 2, Terminated 1 |
| Phase 2 | 2 | Completed 2 |
| Not applicable | 1 | Completed 1 |
Follow DiGeorge Anomaly: new trials by email Literature Review of DiGeorge Anomaly trials Research Report on DiGeorge Anomaly
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Thymus Transplantation Safety-Efficacy Cultured Thymus Tissue - Complete DiGeorge Anomaly, DiGeorge Syndrome | Not applicable | Completed | Sumitomo Pharma Switzerland GmbH | 29 | 2010-12-01 | 2025-01-16 |
| Serum-Free Thymus Transplantation in DiGeorge Anomaly Serum Free Thymus Transplantation with Immunosuppression, Serum Free Thymus Transplantation without immunosuppression - DiGeorge Anomaly | Phase 1 | Terminated | Sumitomo Pharma Switzerland GmbH | 2 | 2008-04-01 | 2022-04-01 |
| Phase I/II Thymus Transplantation With Immunosuppression #950 Cultured Thymus Tissue for Implantation (CTTI), Cultured Thymus Tissue Implantation and Parental Parathyroid Transplantation, Blood Draw - DiGeorge Anomaly, Complete DiGeorge Anomaly | Phase 1 / Phase 2 | Completed | Sumitomo Pharma Switzerland GmbH | 14 | 2005-12-19 | 2022-03-25 |
| Thymus Transplantation Dose in DiGeorge #932 Cultured Thymus Tissue Implantation (CTTI), Cultured Thymus Tissue Implantation with Parathyroid Transplantation - DiGeorge Anomaly, DiGeorge Syndrome | Phase 2 | Completed | Sumitomo Pharma Switzerland GmbH | 7 | 2004-09-02 | 2022-03-25 |
| Thymus Transplantation With Immunosuppression Thymus Tissue for Transplantation - DiGeorge Syndrome, DiGeorge Anomaly | Phase 1 | Completed | Sumitomo Pharma Switzerland GmbH | 15 | 2002-07-01 | 2022-04-04 |
DiGeorge Syndrome (5) · Immunologic Deficiency Syndromes (5) · Thymic aplasia (5) · Hypocalcemia (2) · Hypoparathyroidism (2)
22q11 Deletion Syndrome (5) · Abnormalities, Multiple (5) · Cardiovascular Abnormalities (5) · Cardiovascular Diseases (5) · Chromosome Disorders (5) · Congenital Abnormalities (5) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (5) · Craniofacial Abnormalities (5) · Endocrine System Diseases (5) · Genetic Diseases, Inborn (5) · Heart Defects, Congenital (5) · Heart Diseases (5) · Hemic and Lymphatic Diseases (5) · Immune System Diseases (5) · Lymphatic Abnormalities (5)
Thymus Extracts (2) · Transplantation (2) · Antilymphocyte Serum (1) · Blood Specimen Collection (1) · Cyclosporine (1) · Cyclosporins (1) · Daclizumab (1) · Drug Implants (1) · Immunosuppression Therapy (1) · Methylprednisolone (1) · Mycophenolic Acid (1) · Phlebotomy (1) · Prednisolone (1) · Steroids (1) · Tacrolimus (1)
Sumitomo Pharma Switzerland GmbH (5)
United States (4)
M. Louise Markert, MD, PhD (3) · John W. Sleasman, M.D. (1) · M. Louise Markert, M.D., Ph.D (1)
PMID 18035553, PMID 18424759, PMID 18557726, PMID 19066739, PMID 20236866, PMID 17284531, PMID 23607606, PMID 15100156, PMID 15100681, PMID 18155964, PMID 18333898, PMID 20978268, PMID 21565561, PMID 22590644, PMID 23914737
K12HD043494 (5), R01AI047040 (5), R01AI054843 (4), R56AI047040 (2)